Intensive chemo-immunotherapy with vaccines for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new combination of treatments for advanced ovarian, fallopian tube, or peritoneal cancer. It combines chemotherapy and immunotherapy (drugs that help your immune system fight cancer) with a special vaccine made from your own tumor. The goal is to see if this approach is more effective than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage III or IV) ovarian, fallopian tube, or peritoneal cancer that is a specific type called epithelial carcinoma or carcinosarcoma.
- You have not had chemotherapy before and are starting treatment for the first time.
- You are in good enough health to be up and about (able to do light activities, per the ECOG scale).
- You are expected to be able to have surgery to remove the cancer and to receive chemotherapy directly into the abdomen.
- You have a tumor that is large enough to biopsy and provide at least 2 grams of tissue for making the vaccine.
- You are willing to undergo leukapheresis, which is a procedure to collect your white blood cells for making the vaccine.
- Your kidney, liver, and bone marrow functions are within acceptable ranges as shown by blood tests.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study if you could become pregnant.
- You are at least 18 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.